Uncover key drivers, emerging technologies, and competitive movements shaping the invasive fungal infections market from 2026–2035 with trusted insights from The Business Research Company
What total market size is anticipated for the Invasive Fungal Infections Market in 2030?
The market size for invasive fungal infections has experienced consistent expansion in recent years. It is anticipated to grow from $7.91 billion in 2025 to $8.24 billion in 2026, reflecting a compound annual growth rate (CAGR) of 4.1%. The historic period’s growth can be linked to factors such as the increasing prevalence of HIV and cancer patients, the widespread application of broad-spectrum antibiotics, the established use of amphotericin B in hospitals, a rise in organ transplant procedures, and the growing incidence of hospital-acquired fungal infections.
The invasive fungal infections market is projected to experience significant expansion in the upcoming years. It is expected to grow to $10.1 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.2%. This growth over the forecast period can be attributed to the introduction of novel antifungal drug classes, a heightened awareness of antifungal resistance, the expansion of critical care infrastructure, improved diagnostic capabilities for fungal infections, and increasing investment in infectious disease research. Prominent trends anticipated during this period include a rising incidence of invasive fungal infections in immunocompromised patients, the increasing adoption of echinocandins as a primary therapy, the growing utilization of combination antifungal treatment strategies, the expansion of hospital-based antifungal stewardship programs, and an escalating demand for both broad-spectrum and targeted antifungal agents.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13189&type=smp
What Drivers Are Influencing Production Trends In The Invasive Fungal Infections Market?
The growing number of individuals affected by human immunodeficiency virus (HIV) is anticipated to boost the expansion of the invasive fungal infection market in the future. Human Immunodeficiency Virus (HIV) infection is characterized by a virus that impairs the immune system’s capacity to ward off diseases and illnesses. This increasing prevalence of people with weakened immune systems, particularly those with Human Immunodeficiency Virus (HIV) or acquired immunodeficiency syndrome (AIDS), heightens their vulnerability to invasive fungal infections. This, in turn, provides an opportunity for manufacturers to innovate and provide more targeted and potent antifungal medications. For example, data released in July 2025 by the Joint United Nations Programme on HIV/AIDS (UNAIDS), an international organization based in Switzerland, reported that 40.8 million [37.0 million–45.6 million] individuals were living with HIV in 2024. In the same year, approximately 1.3 million [1 million–1.7 million] people contracted new HIV infections, and 630 000 [490 000–820 000] fatalities were attributed to AIDS-related conditions. Consequently, the expanding population affected by human immunodeficiency virus (HIV) is set to stimulate the growth of the invasive fungal infection market.
Which Segment Groups Are Influencing The Invasive Fungal Infections Market?
The invasive fungal infections market covered in this report is segmented –
1) By Disease Type: Candidemia And Invasive Candidiasis, Intra Abdominal Candidiasis, Cryptococcal Meningitis, Esophageal Candidiasis, Histoplasmosis Acute Pulmonary, Other Disease Types
2) By Drug Type: Polyenes, Triazoles, Echinocandins, Flucytosine, Other Drug Types
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Candidemia And Invasive Candidiasis: Bloodstream Infections, Disseminated Candidiasis
2) By Intra-Abdominal Candidiasis: Peritoneal Candidiasis, Abscess Formation
3) By Cryptococcal Meningitis: Primary Cryptococcal Meningitis, Secondary Cryptococcal Meningitis
4) By Esophageal Candidiasis: Acute Esophageal Candidiasis, Chronic Esophageal Candidiasis
5) By Histoplasmosis Acute Pulmonary: Disseminated Histoplasmosis, Chronic Pulmonary Histoplasmosis
6) By Other Disease Types: Aspergillosis, Mucormycosis, Other Rare Fungal Infections
Which Competitive Trends Are Impacting The Structure Of The Invasive Fungal Infections Market?
Major companies operating in the invasive fungal infection market are focusing on innovative products, such as Zisavel capsules, to enhance treatment efficacy, improve patient outcomes, and increase accessibility for individuals affected by serious fungal infections. Zisavel capsules are a generic antifungal medication derived from isavuconazole, specifically designed to treat invasive aspergillosis and mucormycosis. These 100 mg capsules aim to offer an affordable alternative for patients, thereby improving access to effective treatment. For instance, in October 2023, BDR Pharmaceuticals, an India-based generic and specialty pharmaceutical company, launched Zisavel Capsules, a generic antifungal drug, to address invasive aspergillosis and mucormycosis. Zisavel is indicated for the treatment of invasive aspergillosis and mucormycosis, both of which are severe, potentially life-threatening fungal infections. The introduction of Zisavel seeks to make treatment more accessible to patients by significantly lowering costs compared to existing options such as voriconazole and posaconazole.
Who Are The Major Companies Operating In The Invasive Fungal Infections Market?
Major companies operating in the invasive fungal infections market are Pfizer Inc., Merck And Co. Inc., Bayer AG, Abbott Laboratories, GSK plc, Gilead Sciences Inc., Mylan N.V., Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., BioMarin Pharmaceutical Inc., Xellia Pharmaceuticals, Basilea Pharmaceutica, Cidara Therapeutic Inc., Pulmocide Ltd., NovaBiotics Ltd, F2G Ltd., Giner Inc., Ciron Drugs And Pharmaceuticals Pvt. Ltd., Hexima Limited, Scynexis Inc., Enzon Pharmaceuticals Inc., Matinas BioPharma Holdings Inc., Biosergen AB
Access The Complete Report For Deeper Market Insights:
https://www.thebusinessresearchcompany.com/report/invasive-fungal-infections-global-market-report
Which Region Is Anticipated To See The Fastest Growth In The Invasive Fungal Infections Market?
North America was the largest region in the invasive fungal infections market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the invasive fungal infections market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Invasive Fungal Infections Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=13189&type=smp
Browse Through More Reports Similar to the Global Invasive Fungal Infections Market 2026, By The Business Research Company
Aspergillosis Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/aspergillosis-treatment-global-market-report
Antifungals Market Report 2026
https://www.thebusinessresearchcompany.com/report/antifungals-global-market-report
Systemic Aspergillosis And Systemic Candidiasis Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model